VIA
STRO icon

Virtus Investment Advisers’s Sutro Biopharma STRO Stock Holding History

Virtus Investment Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,827
Closed -$98.1K – 378
2023
Q3 		$98.1K Hold
2,827
– – 0.07% 223
2023
Q2 		$131K Hold
2,827
– – 0.09% 224
2023
Q1 		$131K Buy
+2,827
New +$179K 0.09% 232

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Virtus Investment Advisers's STRO Position: Q4 2023 in Review

Virtus Investment Advisers sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 2,827 shares — an estimated $98.1K sold.

Virtus Investment Advisers first reported a position in STRO in Q1 2023 and held it in 3 quarters. The position peaked at $131K in Q2 2023. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

  • Virtus Investment Advisers reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
  • Virtus Investment Advisers sold 2,827 Sutro Biopharma shares in Q4 2023, an estimated $98.1K.
  • Virtus Investment Advisers first reported a position in Sutro Biopharma in Q1 2023 and held it in 3 quarters.
  • Virtus Investment Advisers's Sutro Biopharma position peaked at $131K in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Virtus Investment Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.